I am aware of the link between selegiline use and impulse control disorders. I believe this is true but perhaps selegiline's role in this is more of a case of facilitating a trigger in certain individuals. Perhaps a person is more prone to this if bipolar or schizophrenic. The pro-sexual effects I referred to was benefits such as improved sexual performance, increased arousal, and perhaps most importantly a slowing down in the decline of sexual activity.
Yes you are right, indeed the study does make use of wistar rats. Although rats and humans will certainly have different outcomes, they do mention some effects that carry over:
"Very low doses of (-)deprenyl increase catecholtiergic activity in the brain (1).
This catecholaminergic activity enhancer (0%) effect was assumed to be responsible for the
peculiar consequences of long lasting treatment with (-)deprenyl (2,3,4), that is an aging rat performs better sexually and lives longer than its untreated control (5,6,7). Likewise, a (-)deprenyl
treated Parkinsonian patient deteriorates slowly (8,9,10) and lives longer"
Also interesting:
"Why does, however, as shown in Fig.2, a small, 1 mg/kg dose of (-)PPAP make a tetrabenatie treated rat capable to escape successfully in the shuttle box? In the light of the preceding analysis, our assumption is that (-)PPAP stimulates coupling of action potential to
transmitter release in the catecholaminergic neurons, thus, a higher number of vesicles leave the
neurons in response to stimulation, suffient for successful performance in the shuttle box. Since
action potential induced increase in cytosolic Ca*+ is required for the fusion of the transmitter
vesicles with the plasma membrane, (-)deprenyl and (-)PPAP may increase cytosolic Ca*+ levels in
response to stimulation"
"All in all, the results presented are substantially supporting the conchrsion that the peculiar
CAE effect exerted by (-)deprenyl and (-)PPAP in the pharmacologically active lowest dose-range
is realized via the stimulation of action potential-transmitter release coupling in the
catecholaminergic neurons of the brain by increasing cytosolic Car+ levels to stimulation. The assumption is that, in very low doses, (-)deprenyl and (-)PPAP act either by mimicking the effect of or activate or mobilize hitherto undetected, highly potent endogenous
CAE substances. The endogenous CAE substances, for which circumstantial evidence was presented previously (12,21), are thought to regulate the catechohtminergic activity of the brain. This is the direct on for future work."
Edited by fall, 25 January 2025 - 10:52 PM.